Cabaletta Bio (CABA) Stock Price, News & Analysis

Company Overview

Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on developing engineered T-cell therapies for patients with autoimmune diseases. The company’s approach is designed to selectively target and eliminate disease-causing B cells or autoreactive immune cells while seeking to restore a healthier immune system.

Cabaletta’s lead program is CABA-201, a fully human CD19-directed chimeric antigen receptor T-cell therapy being evaluated across multiple autoimmune conditions. The company has also developed a platform for creating targeted cellular therapies, including investigational product candidates intended for diseases such as pemphigus and other antibody-mediated autoimmune disorders.

Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Cabaletta Bio conducts research and clinical development primarily in the United States. Its therapies remain investigational and are being evaluated in clinical studies; they have not been established as safe or effective for commercial use by regulatory authorities.

Key Stats

• Today's Range: $1.78 to $1.94
• 50-Day Range: $1.89 to $3.57
• 52-Week Range: $1.78 to $4.23
• Volume: 4.83 million shs
• Average Volume: 4.11 million shs
• Market Capitalization: $303.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.60
• Consensus Rating: Moderate Buy

Cabaletta Bio Stock Analysis - MarketRank™

Cabaletta Bio scored higher than 50% of companies evaluated by MarketBeat, and ranked 558th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cabaletta Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 2 strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Cabaletta Bio has a consensus price target of $15.60, representing about 771.5% upside from its current price of $1.79.

Amount of Analyst Coverage

Cabaletta Bio has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cabaletta Bio are expected to grow in the coming year, from ($1.34) to ($1.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cabaletta Bio is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cabaletta Bio is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cabaletta Bio has a P/B Ratio of 1.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

24.34% of the float of Cabaletta Bio has been sold short.

Short Interest Ratio / Days to Cover

Cabaletta Bio has a short interest ratio ("days to cover") of 6.3.

Change versus previous month

Short interest in Cabaletta Bio has recently increased by 15.87%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cabaletta Bio does not currently pay a dividend.

Dividend Growth

Cabaletta Bio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

Cabaletta Bio has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Cabaletta Bio this week, compared to 3 articles on an average week.

Search Interest

Only 10 people have searched for CABA on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

MarketBeat Follows

3 people have added Cabaletta Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cabaletta Bio insiders have not sold or bought any company stock.

Percentage Held by Insiders

6.44% of the stock of Cabaletta Bio is held by insiders.

Percentage Held by Institutions

Cabaletta Bio has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 10/12/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CABA
• CIK: 1759138
• Web: www.cabalettabio.com
• Phone: 267-759-3100
• Fax: N/A
• Employees: 158
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Cabaletta Bio: $15.60
• High Price Target: $30.00
• Low Price Target: $3.00
• Potential Upside/Downside: +771.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.89
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.57)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$167.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -128.27%
• Return on Assets: -95.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.79
• Quick Ratio: 5.79

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.16 per share
• Price / Book: 1.54

Miscellaneous

• Outstanding Shares: 169,545,000
• Free Float: 158,626,000
• Market Cap: $303.49 million
• Optionable: Optionable
• Beta: 3.48